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Abstract
Background: The functional polymorphism that explains the established association of the androgen receptor (AR) with
androgenetic alopecia (AGA) remains unidentified, but Copy Number Variation (CNV) might be relevant. CNV involves
changes in copy number of large segments of DNA, leading to the altered dosage of gene regulators or genes themselves.
Two recent reports indicate regions of CNV in and around AR, and these have not been studied in relation to AGA. The aim
of this preliminary case-control study was to determine if AR CNV is associated with AGA, with the hypothesis that CNV is
the functional AR variant contributing to this condition.
Methodology/Principal Findings: Multiplex Ligation-dependent Probe Amplification was used to screen for CNV in five AR
exons and a conserved, non-coding region upstream of AR in 85 men carefully selected as cases and controls for maximal
phenotypic contrast. There was no evidence of CNV in AR in any of the cases or controls, and thus no evidence of significant
association between AGA and AR CNV.
Conclusions/Significance: The results suggest this form of genomic variation at the AR locus is unlikely to predispose to
AGA.
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Introduction
The importance of the gene encoding the androgen receptor
(AR; NCBI NM_000044) in the development of androgenetic
alopecia (AGA; OMIM %300710) is now well established. Our
initial observation [1] of genetic association of AR with AGA has
been replicated in three independent studies [2–4]. Although
association with several single nucleotide polymorphisms (SNPs)
has been demonstrated, none have proven causative. We have
shown that known AR coding sequence polymorphisms such as
triplet repeats are not associated with AGA [5], and mutation
screening has identified no other relevant coding sequence
mutations. Other forms of variation that might affect gene
expression should now be considered.
Copy Number Variation (CNV) has been recognised recently as
a common form of genomic variation [6–8] in which DNA
segments (.1 kb) are altered in copy number compared to a
reference genome. Recent reports have suggested that up to 12%
of the genome is subject to CNV, accounting for at least 1% of
genetic variation [6,9].
CNV has been reported in the region of AR [6,8] and SNPs can
be co-inherited in linkage disequilibrium (LD) with CNV [6]. As
CNV might result in variable copies of genetic regulatory regions
or copies of the gene itself, such variation might underpin the
tissue- and developmental stage-specific abnormalities in expres-
sion of AR seen in men predisposed to AGA.
We hypothesised that AR CNV could be associated with AGA.
Therefore, our approach was to first search for evidence of CNV




The study was approved by the Ethics Review Committee of the
Alfred Hospital Melbourne, and informed consent was obtained
from each participant. Subjects were drawn from the population-
based Victorian Family Heart Study cohort [10]. AGA phenotypes
were gathered by way of direct assessment by trained observers
and validated questionnaires [11]. Cases were 34 men aged 20–30
years (mean 27 years) with cosmetically significant baldness
(Hamilton-Norwood types III vertex to VII, median type IV),
and controls were 51 men aged 54–68 years (mean 56 years) with
no indication of baldness (Hamilton-Norwood type I).
MLPA analysis
Peripheral blood was collected from each subject, and DNA was
extracted using standard phenol-chloroform methods. Multiplex
Ligation-Dependent Probe Analysis (MLPA) was performed to
detect the presence of CNV around AR. Six probes were selected
to test AR exons and one upstream non-coding region for the
presence of CNV (probes 1 – 6; Table 1 and Figure 1). Two
PLoS ONE | www.plosone.org 1 April 2009 | Volume 4 | Issue 4 | e5081Figure 1. Location of the probes in relation to the androgen receptor. Diagrammatic representation of part of chromosome6showing the
androgen receptor (AR) and the upstream (EDA2R) and downstream (OPHN1) genes. The relative locations of the upstream region (probe 1) and the
five probes within the exons of AR are represented by the arrows. The AR gene exons are represented as boxes, as is the location of prior evidence of
copy number variation (CNV) in this region.
doi:10.1371/journal.pone.0005081.g001
Table 1. Sequences and genomic locations of the probes.
Probe Genomic Location Sequence
1 ChrX: 66,481,078–66,481,135 59 GGGTTCCCTAAGGGTTGGAGACTTAAGGGTACATAATAATGGGCAGTGG 39
59 ATTATGTGGACACCACAATTTGGAAGGGTCTAGATTGGATCTTGCTGGC 39
2 ChrX: 66,681,149–66,681,198 59 GGGTTCCCTAAGGGTTGGAGCTTCAGCACTGCAGCCACGACCC 39
59 GCCTGGTTAGGCTGCACGCGGAGAGATCTAGATTGGATCTTGCTGGC 39
3 ChrX: 66,822,629–66,822,690 59 GGGTTCCCTAAGGGTTGGACCGAAGGAAAAATTGTCCATCTTGTCGTCT 39
59 TCGGAAATGTTATGAAGCAGGGATGACTCTGGTCTAGATTGGATCTTGCTGGC 39
4 ChrX: 66,854,045–66,854,113 59 GGGTTCCCTAAGGGTTGGAGCTTCCGCAACTTACACGTGGACGACCAGATGGCT 39
59 GTCATTCAGTACTCCTGGATGGGGCTCATGGTGTCTAGATTGGATCTTGCTGGC 39
5 ChrX: 66,858,400–66,858,453 59 GGGTTCCCTAAGGGTTGGAGTACCGCATGCACAAGTCCCGGATGTA 39
59 CAGCCAGTGTGTCCGAATGAGGCACCTTCTAGATTGGATCTTGCTGGC 39
6 ChrX: 66,860,242–66,860,342 59 GGGTTCCCTAAGGGTTGGACGAGAGAGCTGCATCAGTTCACTTTTGACCTGCTAATCAAG 39
59 TCACACATGGTGAGCGTGGACTTTCCGGAAATGATGGCAGAGATCTAGATTGGATCTTGCTGGC 39
7 Chr16: 3,772,843–3,772,914 59 GGGTTCCCTAAGGGTTGGACCAGCTAGTGGAATTCAAAACACAATTGGTTCTGTTGGCACA 39
59 GGGCAACAGAATGCCACTTCTTTAAGTAACTCTAGATTGGATCTTGCTGGC 39
8 Chr22: 39,857,407–39,857,482 59 GGGTTCCCTAAGGGTTGGACCAACCTAAGCACTGTTAGTCAGATTGATCCCAGCTCCAT 39
59 GAAAGAGCCTATGCAGCTCTTGGACTACCCTATCATCTAGATTGGATCTTGCTGGC 39
Listed are the AR exonic and non-coding region probes (1–6), and control probes (7 and 8). Probes 7 and 8 were used as controls to normalize data and were designed
in regions with no known CNV. Genomic location data based on human reference sequence (NCBI Build 36.1).
doi:10.1371/journal.pone.0005081.t001
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reference point controls (Table 1). Peak heights were analysed for
the eight probes for each DNA sample, as outlined in White et al
[12]. Briefly, peak heights for each probe were standardized to
controlpeaks and the median ratio for each probe normalised to 1.0
[12]. We set threshold values for duplication and deletions of 1.5
and 0.5 respectively [13]. All samples were analysed at least twice.
Results
Figure 2 shows data for each of the six AR test probes in all case-
control subjects. The standard deviation for each of the six AR test
probes was within 15%, except for probes 2 and 6 which were
slightly higher, possibly suggesting less reliable performance of the
probes. Nevertheless, across the remaining samples, good coverage
of the AR region was achieved by the higher performing probes,
and the results provide no evidence of CNV in this region, either
as deletion or duplication, in cases or controls.
Discussion
This study examined CNV in and around AR and their
potential relationship with AGA. CNV may contribute to
differences in gene expression through duplications or deletions
of genes or gene regulatory elements [14], and may in part
account for genetic predisposition to common complex conditions
such as AGA. However, we found no evidence of CNV in the
regions of the AR that we examined. Insofar as our original
hypothesis, we could therefore find no evidence of association of
CNV with AGA.
Although data generated by probes 2 and 6 showed relatively
high standard deviations, casting doubt on their reliability, the AR
gene was well covered by the remaining probes. The lack of
evidence for CNV at this locus supports the findings of a very
recent study by McCarroll et al which has demonstrated a lack of
CNV in the AR coding regions [15].
This study examined a locus on chromosome 6 in males,
meaning that if changes in CNV dosages were detected, they
would be expected to be at either a 0 (deletion) or 2 (duplication)
level. Figure 2 demonstrates that the results for some samples
showed normalised ratios of around 0.5 or 1.5, consistent with
possible mosaicism within the cells of the blood samples from
which the DNA was extracted. CNV mosaicism has been
demonstrated in blood samples in monozygotic twins [16], and
it is known that CNV may be variable between cell types within
Figure 2. (a-f): Normalised ratios for both case and control samples across the six test probes. Each plot includes at least two replicates
per sample represented by the same symbol, with the symbols alternating between each sample. Samples were normalised using two control probes
(see Table 1). Normal range 0.5–1.5.
doi:10.1371/journal.pone.0005081.g002
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no evidence of AR CNV in DNA derived from lymphocytes, we
cannot rule out CNV around the AR in DNA contained in the cells
of the hair follicles themselves.
Our preliminary investigation did not thoroughly investigate the
downstream non-coding flanking region and other more distant
sites from AR. However, we focussed on a region that we have
already shown to be strongly associated with AGA and it would be
likely that causative CNV, if they exist, would be in the region
examined. Sample sizes used were relatively small, however power
is augmented by the fact that association of AGA with AR is well-
established and that the cases and controls were selected to
represent high phenotypic contrast.
In the absence of evidence of AR CNV involvement in AGA,
other forms of non-coding AR sequence variation, and also
epigenetic mechanisms at this locus, should be considered in
clarifying the role of AR as a genetic risk locus for AGA.
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